Study on Adding Cemiplimab to Chemotherapy Before Surgery for Patients with Sinonasal Squamous Cell Carcinoma

Program Overview

This study is exploring if combining cemiplimab, an immunotherapy drug, with chemotherapy drugs carboplatin and paclitaxel before surgery can better control sinonasal squamous cell carcinoma compared to chemotherapy alone. The usual treatment involves surgery followed by radiation, sometimes with chemotherapy. By adding cemiplimab before surgery, researchers hope to stop the cancer from growing or spreading more effectively.

Description

The main goal of this study is to see if adding cemiplimab to chemotherapy before surgery can improve the time patients live without the cancer coming back. Researchers will compare the results of patients receiving cemiplimab with those receiving only chemotherapy. They will also look at how well the cancer responds to treatment, overall survival rates, and any side effects.

Patients will be randomly assigned to one of two groups. In the first group, patients will receive cemiplimab along with carboplatin and paclitaxel through an IV every three weeks for up to two cycles before surgery. In the second group, patients will receive only carboplatin and paclitaxel on the same schedule. After this initial treatment, patients will be evaluated and proceed to further therapy based on their response.

After surgery, patients may receive additional chemotherapy and radiation therapy to help prevent the cancer from returning. Throughout the study, patients will undergo various scans and tests to monitor their health and the cancer's response to treatment. Follow-up visits will continue for up to five years to track long-term outcomes.

Eligibility Criteria

Locations